<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<oembed>
  <author_name>Tatsu21</author_name>
  <author_url>https://blog.hatena.ne.jp/Tatsu21/</author_url>
  <blog_title>レジデントノート</blog_title>
  <blog_url>https://tatsu21.hatenablog.com/</blog_url>
  <categories>
  </categories>
  <description>Q: Preferred term for “progression-free survival” A: “Progression-free interval” The time from when a Tx is started until that Tx is no longer controlling the cancer Q: Checkpoint inhibitor toxicity A: Autoimmune disease Checkpoint inhibitors: a type of cancer immunotherapy that works by blocking pr…</description>
  <height>190</height>
  <html>&lt;iframe src=&quot;https://hatenablog-parts.com/embed?url=https%3A%2F%2Ftatsu21.hatenablog.com%2Fentry%2F2025%2F10%2F28%2F062731&quot; title=&quot;Oncology F - レジデントノート&quot; class=&quot;embed-card embed-blogcard&quot; scrolling=&quot;no&quot; frameborder=&quot;0&quot; style=&quot;display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;&quot;&gt;&lt;/iframe&gt;</html>
  <image_url></image_url>
  <provider_name>Hatena Blog</provider_name>
  <provider_url>https://hatena.blog</provider_url>
  <published>2025-10-28 06:27:31</published>
  <title>Oncology F</title>
  <type>rich</type>
  <url>https://tatsu21.hatenablog.com/entry/2025/10/28/062731</url>
  <version>1.0</version>
  <width>100%</width>
</oembed>
